{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:32:00Z","timestamp":1790310720524,"version":"4.1.0"},"reference-count":24,"publisher":"Korean Cancer Association","issue":"4","license":[{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["6-2018-0160"],"award-info":[{"award-number":["6-2018-0160"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["62543943"],"award-info":[{"award-number":["62543943"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2023,10,15]]},"abstract":"<jats:p>Purpose Frequent neutropenia hinders uninterrupted palbociclib treatment in patients with hormone receptor (HR)\u2013positive breast cancer. We compared the efficacy outcomes in multicenter cohorts of patients with metastatic breast cancer (mBC) receiving palbociclib following conventional dose modification or limited modified schemes for afebrile grade 3 neutropenia.Materials and Methods Patients with HR-positive, human epidermal growth factor receptor 2\u2013negative mBC (n=434) receiving palbociclib with letrozole as first-line therapy were analyzed and classified based on neutropenia grade and afebrile grade 3 neutropenia management as follows: group 1 (maintained palbociclib dose, limited scheme), group 2 (dose delay or reduction, conventional scheme), group 3 (no afebrile grade 3 neutropenia event), and group 4 (grade 4 neutropenia event). The primary and secondary endpoints were progression-free survival (PFS) between groups 1 and 2 and PFS, overall survival, and safety profiles among all groups.Results During follow-up (median 23.7 months), group 1 (2-year PFS, 67.9%) showed significantly longer PFS than did group 2 (2-year PFS, 55.3%; p=0.036), maintained across all subgroups, and upon adjustment of the factors. Febrile neutropenia occurred in one and two patients of group 1 and group 2, respectively, without mortality.Conclusion Limited dose modification for palbociclib-related grade 3 neutropenia may lead to longer PFS, without increasing toxicity, than the conventional dose scheme.<\/jats:p>","DOI":"10.4143\/crt.2022.1543","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T08:22:48Z","timestamp":1681201368000},"page":"1198-1209","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor\u2013Positive Metastatic Breast Cancer"],"prefix":"10.4143","volume":"55","author":[{"given":"Seul-Gi","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sejung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gun Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Ye","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Seok","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hwan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabsoo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Don","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Hae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohyuk","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2954","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1607303"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.1000"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1609709"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.78.9909"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.4782"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.75.6155"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1903765"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30642-2"},{"key":"ref9","first-page":"3987","volume-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","author":"Johnston","year":"2020"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.02.011"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.26"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-1421"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2419"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05750-y"},{"key":"ref15","volume-title":"IBRANCE (palbociclib)","year":"2018"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy181"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.902"},{"key":"ref18","first-page":"1205","volume-title":"Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B","author":"Budman","year":"1998"},{"key":"ref19","first-page":"1440","volume-title":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials","year":"2019"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7286"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2016.03.014"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.8415"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1810527"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1200\/jgo.18.00173"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2022-1543.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2022.1543","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2022-1543.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T07:16:00Z","timestamp":1697181360000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2022.1543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,15]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2022.1543","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,15]]},"assertion":[{"value":"2022-11-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-11","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}